Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_007294.4(BRCA1):c.70_80delTGTCCCATCTG(p.Cys24fs) variant causes a frameshift, splice region change. The variant allele was found at a frequency of 0.00000124 in 1,609,128 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★★).
BRCA1 (HGNC:1100): (BRCA1 DNA repair associated) This gene encodes a 190 kD nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The BRCA1 gene contains 22 exons spanning about 110 kb of DNA. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2020]
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant located near the start codon (<100nt), not predicted to undergo nonsense mediated mRNA decay. There are 1690 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 17-43124016-CCAGATGGGACA-C is Pathogenic according to our data. Variant chr17-43124016-CCAGATGGGACA-C is described in ClinVar as [Pathogenic]. Clinvar id is 55676.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr17-43124016-CCAGATGGGACA-C is described in Lovd as [Pathogenic]. Variant chr17-43124016-CCAGATGGGACA-C is described in Lovd as [Pathogenic].
Breast-ovarian cancer, familial, susceptibility to, 1 Pathogenic:6
Pathogenic, criteria provided, single submitter
clinical testing
Counsyl
Mar 28, 2017
- -
Pathogenic, criteria provided, single submitter
clinical testing
All of Us Research Program, National Institutes of Health
Nov 27, 2023
This variant deletes the last 11 nucleotides in exon 2 in the BRCA1 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant is also known as 188del11 and 189del11 in the literature. This variant has been detected in over 10 individuals and families affected with breast and ovarian cancer (PMID: 7837387, 8651293, 10498392, 18779604, 22711857, 25682074, 26543556) and one individual each affected with endometrial (PMID: 8651293) and pancreatic cancer (PMID: 28767289). This variant has been identified in 21 families among the CIMBA participants (PMID: 29446198) (https://cimba.ccge.medschl.cam.ac.uk/). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -
Pathogenic, criteria provided, single submitter
clinical testing
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge
Oct 02, 2015
- -
Pathogenic, no assertion criteria provided
clinical testing
Breast Cancer Information Core (BIC) (BRCA1)
Feb 20, 2004
- -
Pathogenic, reviewed by expert panel
curation
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA)
Apr 22, 2016
Variant allele predicted to encode a truncated non-functional protein. -
Pathogenic, criteria provided, single submitter
clinical testing
Baylor Genetics
Mar 29, 2024
- -
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter
clinical testing
Genetic Services Laboratory, University of Chicago
Jan 21, 2022
DNA sequence analysis of the BRCA1 gene demonstrated a 11 base pair deletion in exon 2, c.70_80del. This pathogenic sequence change results in an amino acid frameshift and creates a premature stop codon 12 amino acids downstream of the change, p.Cys24Serfs*13. This pathogenic sequence change is predicted to result in an abnormal transcript, which may be degraded, or may lead to the production of a truncated BRCA1 protein with potentially abnormal function. The c.70_80del sequence change has not been described in the population databases such as ExAC and gnomAD (dbSNP rs1220450191). This pathogenic sequence change has previously been described in an individual with breast cancer and ovarian cancer (PMID: 7837387, 10498392, 25682074, 22711857, 26543556). -
Pathogenic, criteria provided, single submitter
clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano
Jul 22, 2022
This variant alters the translational reading frame of the BRCA1 mRNA and causes the premature termination of BRCA1 protein synthesis. It has not been reported in large, multi-ethnic general populations (http://gnomad.broadinstitute.org). In the published literature, this variant has been reported in individuals with breast cancer, PMIDs: 22711857 (2012), 26543556 (2015), and 25682074 (2015)) and pancreatic cancer (PMID: 28767289 (2017)). Based on the available information, this variant is classified as pathogenic. -
Pathogenic, criteria provided, single submitter
clinical testing
GeneDx
Jul 18, 2023
Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed in large population cohorts (gnomAD); Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; Also known as 189_199del11 or c.69_79delGTGTCCCATCT; This variant is associated with the following publications: (PMID: 16267036, 7837387, 7545954, 18779604, 26543556, 8651293, 12402332, 10498392, 8533757, 28767289, 31090900, 30787465, 31464824, 25682074, 36098958, 34022715, 34887416) -
Hereditary breast ovarian cancer syndrome Pathogenic:3
Pathogenic, criteria provided, single submitter
clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Apr 14, 2022
Variant summary: BRCA1 c.70_80del11 (p.Cys24SerfsX13) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 251038 control chromosomes.The variant, c.70_80del11, has been reported in the literature in multiple individuals affected with breast and/or ovarian cancer (eg. Berman_1996, Hopper_1999, Alsop_2012, Dean_2015, Wong-Brown_2015). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Nine ClinVar submissions including one expert panel (ENIGMA) have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All submitters classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
Pathogenic, criteria provided, single submitter
clinical testing
Labcorp Genetics (formerly Invitae), Labcorp
Jan 05, 2024
This sequence change creates a premature translational stop signal (p.Cys24Serfs*13) in the BRCA1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA1 are known to be pathogenic (PMID: 20104584). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with breast cancer and ovarian cancer (PMID: 2246425, 7837387, 10498392, 20104584, 22711857, 25682074, 26543556). This variant is also known as 188del11 and 189del11. ClinVar contains an entry for this variant (Variation ID: 55676). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. -
Pathogenic, no assertion criteria provided
research
Research Molecular Genetics Laboratory, Women's College Hospital, University of Toronto
The c.70_80del11 pathogenic mutation, located in coding exon 1 of the BRCA1 gene, results from a deletion of 11 nucleotides at nucleotide positions 70 to 80, causing a translational frameshift with a predicted alternate stop codon (p.C24Sfs*13). This mutation has been reported in multiple individuals with hereditary breast, ovarian, and/or pancreatic cancer (Berman DB et al. Am. J. Hum. Genet. 1996 Jun;58:1166-76; Frank TS et al. J. Clin. Oncol. 2002 Mar;20:1480-90; Kurian A et al. J. Clin. Oncol. 2008 Oct;26(29):4752-8; Shindo K et al. J. Clin. Oncol. 2017 Oct;35(30):3382-3390). Of note, this alteration is also designated as 188del11 and 189del11 in published literature. In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Pathogenic, criteria provided, single submitter
clinical testing
Color Diagnostics, LLC DBA Color Health
Apr 19, 2022
This variant deletes the last 11 nucleotides in exon 2 in the BRCA1 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant is also known as 188del11 and 189del11 in the literature. This variant has been detected in over 10 individuals and families affected with breast and ovarian cancer (PMID: 7837387, 8651293, 10498392, 18779604, 22711857, 25682074, 26543556) and one individual each affected with endometrial (PMID: 8651293) and pancreatic cancer (PMID: 28767289). This variant has been identified in 21 families among the CIMBA participants (PMID: 29446198) (https://cimba.ccge.medschl.cam.ac.uk/). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -